Alterity Therapeutics Ltd.ASX: ATH

Changes to Managing Director Terms of Employment

· Issued by Alterity Therapeutics Ltd. via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Alterity Therapeutics Ltd. has announced changes to the remuneration package of its Managing Director, Dr. David Stamler, following a review by the Board of Directors. The revised remuneration package will take effect from mid-October and includes a summary of material terms that will be presented for shareholder approval at the upcoming annual general meeting. This announcement was authorized by the Board of Alterity Therapeutics Ltd.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/changes-to-managing-director-terms-of-employment

Release

Changes to Managing Director Remuneration and Terms of Employment MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 October 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for...

Alterity Therapeutics Ltd. on 6ix

Earlier from Alterity Therapeutics

Later from Alterity Therapeutics

All Alterity Therapeutics news releases